European Immunotherapy Net
The central resource platform for healthcare professionals and patients, giving you the latest news and updates on all areas of immunotherapy.
European Immunotherapy Net
The European Immunotherapy Net brings you the latest news and updates on all areas of immunotherapy. This platform offers healthcare professionals, nurses and patients access to the best in scientific publications, research, continuing medical education and more via a digital community that nurtures a transparent exchange of ideas, information, and activities. Powered by the European Hematology Association.
The challenge of COVID-19: EBMT recommendations for management of transplant and CAR T-cell therapy patients
Browse all scientific publicationsLatest News
EHA and EBMT join forces in the GoCART coalition to advance cellular therapy in Europe.
EHA joins EBMT in a newly founded GoCART coalition aimed at positioning Europe in the lead of the global cellular therapy field for hematological diseases. GoCART aims to promote patient access to novel cellular therapies and to contribute health and well-being through innovation by multi-stakeholder collaboration.
CAR T-Cell Research Surges
Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since the first such treatment received approval in 2017. Hundreds of trials are under way, 3 therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma (MM).
Bispecific anti-CD20 and anti-CD19 CAR T Cell Therapy Shows Efficacy in B Cell Malignancies in Phase 1 Trial
Nirav N. Shah, MD, an associate professor at the Medical College of Wisconsin, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor (CAR) T cells in a phase 1 dose escalation and expansion trial (NCT03019055) for relapsed B cell malignancies.
Research Highlights
Scientific Publications
Browse our collection of scientific publications on Immunotherapy to learn more about the latest research and developments in the field.
Read more
Grants
EHA Research Grants support talented junior researchers in advancing their career, e.g. towards becoming the leader of a research group. If you have ambition for advancing your career and you have the support of your department and institute, apply now! The current call for applications will close on December 16, 2020.
Read more
Education Higlights
EHA CAR-T Program
An 8-course program covering all aspects of CAR-T; mechanisms of action, the process of CAR-T manufacture and infusion, treatment of hematopoietic malignancies and patient selection, CRS, and other complications as well as ethics and consent, multidisciplinary care and regulatory aspects.
Read more
Lymphodepletion optimization for CAR T-cell therapy
At the 8th annual meeting of the Society of Hematologic Oncology (SOHO), Elizabeth Budde presented how the process of lymphodepletion can be optimized to aid persistence and efficacy of infused CAR T-cells.
Read more
Patient Highlights
Pediatrics
Whether you are a health care practitioner looking to expand your knowledge or a carer explaining immunotherapy to a child or its family for the first time, we are here to help. Explore the resource library for an overview of resources relating to pediatric patients.
Access resource library
Adults
While Immunotherapy has the power to change lives, it can be hard to find the information and support you need during treatment. Get an overview of the best information that will help you to understand your treatment, and direct you to the support you need by exploring the resource library.
Acess resource library
Nurses Highlights
Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma
Anwer, an oncologist, physician-scientist, and stem cell transplant staff physician at the Taussig Cancer Center of Cleveland Clinic, discussed the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.
Read more
CAR T-Cell Therapy: High Response Rates, High Toxicity Rates
Andrew D. Zelenetz, MD, PhD, medical oncologist and medical director of quality informatics at Memorial Sloan Kettering Cancer Center recently discussed CAR T-cell therapy for this patient population at the NCCN 2020 Virtual Congress on Hematologic Malignancies.
Read more